BioPharmaSpec announced the launch of “The BioPharmaSpec Approach” for MS-based detection of Host Cell Proteins (HCPs). The new in-house service allows Clients access to a pre-existing approach that the company says detects a wider population of HCPs than possible with traditional ELISA technologies.

In contrast to HCP-ELISA, which relies on the presence of polyclonal antibodies for positive HCP detection, The BioPharmaSpec Approach has the distinct advantage of detecting HCPs in a de novo manner, without specialized polyclonal antibody reagents or product / process-specific method development. 

Dr Andrew Reason, chief executive officer at BioPharmaSpec, said, “Through our significant experience, high-end MS technologies and intuitive, specialized software, our clients have been progressively adopting MS as technique for analyzing HCPs in their products. In turn, this trend has swayed regulatory groups worldwide, who now often recommend the use of MS as an orthogonal approach to HCP-ELISA.”